TPS® | IDL Biotech
IDL Biotech

CLOSE MENU

TPS®

TPS® is a tumor activity marker assay used to support prognosis, treatment monitoring, and patient follow-up for various epithelial cancers, including breast, colorectal, ovarian, and prostate cancer.

 

TPS® measures soluble fragments of cytokeratin 18, which is over-expressed in epithelial cells and particularly in many types of cancer. This information is crucial for early detection of cancer recurrence and the quick assessment of treatment efficacy.

 

Cytokeratins
Most eukaryotic cells have cytoplasmic cytoskeletal structures known as intermediate filaments. The cytoskeletal network is responsible for the mechanical integrity of the cell and it is critical during cellular processes like cell division, motility and cell to cell contacts. At present more than 20 different cytokeratins have been identified, of which cytokeratin 8, 18 and 19 are the most abundant in simple epithelial cells. The cytokeratins are epithelial cell specific and the cytokeratin pattern is usually preserved during the transformation of normal cells into malignant cells.

 

Find more information

The tumor marker TPS® is a reliable indicator of tumor cell activity particularly useful in patient managementfor different carcinomas. Compared with conventional tumor mass markers, the activity marker TPS® provides the clinician with earlier signals about the course of the disease. TPS® is particularly useful in treatment monitoring and surveillance of patients with epithelial cell carcinomas e.g. breast, prostate and
ovarian cancer.

Available in ELISA and IRMA formats.

Clinical evaluation

TPS® is a quantitative immunoassay that specifically measures a defined epitope on cytokeratin 18. The test result is directly proportional to the concentration of soluble cytokeratin fragments in serum and plasma. An elevated level of soluble cytokeratin fragments in patient samples is an indication of epithelial tumor cell activity. By following the patient with repeated assays of TPS® , both during treatment and at follow up, the clinician obtain critical information about the tumor activity during surveillance for early detection of recurrence.

Positive results for TPS®

Results from a Czech Republic study.

Per-Anders Abrahamsson New Scientific Advisor to IDL Biotech AB

Per-Anders Abrahamsson, MD, PhD, Professor in Urology, has been working as urologist for 40 years, out of which 20 years as Head of the Department of Urology, Skåne University Hospital (Malmö/Lund, Trelleborg and Landskrona), Adjunct Secretary General at the European Association of Urology (EAU) 2004-2007 responsible for Science, EAU Secretary General 2007 – 2015, Vice President Global Medical Affairs Uro-oncology, Ferring Pharmaceuticals A/S and Member of the Board at Camurus AB.

What is cytokeratins?

Cancer affects everyone – the young and old, the rich and poor, men, women and children – and represents a tremendous burden on patients, families and societies. Cancer is one of the leading causes of death in the world.

IDL Biotech

Skip this intro